Bryan J. McMichael - 27 Mar 2023 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role: Title: Executive Vice President, Accounting, Corporate Controller and Principal Accounting Officer
Signature: /s/ McDavid Stilwell, as Attorney-in-Fact for Bryan J. McMichael
Issuer symbol: CHRS
Transactions as of: 27 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 29 Mar 2023, 16:30:47 UTC
Previous filing: 24 Jan 2023
Next filing: 15 Jun 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CHRS	Stock Option (Right to Buy)	Award	$0	+25,000		$0.000000	25,000	27 Mar 2023	Common Stock	25,000	$6.00	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1. The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 27, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Remarks:

Title: Executive Vice President, Accounting, Corporate Controller and Principal Accounting Officer